Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
With a market cap of 481.91B, Johnson & Johnson(JNJ) trades at $199.50. The stock has a price-to-earnings ratio of 19.30 and currently yields dividends of 2.5%.
On 2025-11-19, Johnson & Johnson(JNJ) stock traded between a low of $199.50 and a high of $199.50. Shares are currently priced at $199.50, which is 0.0% above the low and 0.0% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 1.07M, against a daily average of 8.36M.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $200.30 and a 52-week low of $140.68.
In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $200.30 and a 52-week low of $140.68.
JNJ News
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
In November 2025, Johnson & Johnson announced several significant milestones, including FDA approvals for new indications of DARZALEX FASPRO® and CAPLYTA, as we...
Hedge funds appear to be rebuilding their defensive playbook, and perhaps the clearest tell is a subtle but broad rotation into heavyweight healthcare names. Re...
Analyst ratings
57%
of 28 ratingsMore JNJ News
Johnson & Johnson (NYSE:JNJ) on Monday agreed to acquire Halda Therapeutics OpCo, Inc. for $3.05 billion in cash. Halda is a clinical-stage biotechnology compa...
Shares in medtech giant Johnson & Johnson (JNJ) rose today as it said it would revolutionize cancer treatment following its $3.05 billion acquisition of “hold a...
Johnson & Johnson (JNJ) said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics, adding on an entirely new platform and...
(RTTNews) - Johnson & Johnson (JNJ) Monday announced new data from the Phase 3b APEX study showing that Tremfya continued to reduce both signs and symptoms of a...
Johnson & Johnson (JNJ) has announced its plan to purchase Halda Therapeutics, a firm focused on developing oral therapies aimed at treating various solid tumor...
(RTTNews) - Johnson & Johnson (JNJ) announced Monday that it has entered into a definitive agreement to acquire biotechnology company Halda Therapeutics OpCo, I...
Johnson & Johnson announced new data from the Phase 3b APEX study showing that Tremfya continued to reduce both signs and symptoms of active psoriatic arthritis...